PTLA’s CMO is resigning for no stated reason: http://www.sec.gov/Archives/edgar/data/1269021/000119312513324147/d581077d8k.htm Perhaps the reason is lack of confidence in the phase-3 program for Betrixaban (#msg-89306565).